Last reviewed · How we verify
NCT03725631
Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD
NA trial testing Imaging and serologic evaluation of fibrosis and steatosis in Nonalcoholic Fatty Liver in 150 participants. Status unknown.
31 August 2019
Quick facts
| Lead sponsor | Korea University Guro Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 150 |
| Start date | 1 September 2016 |
| Primary completion | 31 August 2019 |
| Estimated completion | 31 August 2019 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Imaging and serologic evaluation of fibrosis and steatosis
Conditions studied
- Nonalcoholic Fatty Liver — all drugs for Nonalcoholic Fatty Liver →
- Nonalcoholic Steatohepatitis — all drugs for Nonalcoholic Steatohepatitis →
Sponsor
Korea University Guro Hospital
Who can join
19 and older, any sex, with Nonalcoholic Fatty Liver or Nonalcoholic Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. To evaluate hepatic fibrosis and steatosis using MR imaging, transient elastography (TE), and serum biomarker 2. To develop non-invasive diagnosis marker for NASH and advanced fibrosis
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease.
Lee YS, Yoo YJ, Jung YK, Kim JH, et al · · 2020 · cited 21× · PMID 32251018 · DOI 10.14309/ctg.0000000000000157
Verify or expand the search:
- PubMed search for NCT03725631
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nonalcoholic Fatty Liver
Currently open trials in the same condition.
- NCT07007741 — Digital Therapy for Fatty Liver Disease · NA · recruiting
- NCT05199948 — Weight, Energy, Lipids, and the Liver (WELL) Study · NA · active not recruiting
- NCT04595474 — Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes · active not recruiting
- NCT05165706 — Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance · NA · recruiting
Other Korea University Guro Hospital trials
Trials by the same sponsor.
- NCT07009769 — AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy · completed
- NCT06752733 — Cardiac Stunning After Electrical Cardioversion · active not recruiting
- NCT06202690 — SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC · NA · not yet recruiting
- NCT06889259 — Efficacy and Safety of CBT on Tinnitus · NA · completed
- NCT05704621 — Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Mai · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03725631 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Korea University Guro Hospital
- Last refreshed: 31 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03725631.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing